MedTrace Logo

Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients

NCT00356616 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-01-29

No results posted yet for this study

Summary

To evaluate whether the combined therapy of two nucleosides plus one nucleotide (Trizivir + TDF) manages to keep CD4 lymphocytes stable in patients with HIV infection on antiretroviral treatment that present virological failure and multiple resistance to antiretrovirals.

Conditions

  • HIV Infections

Interventions

DRUG

Trizivir (AZT+3HT+Abacavir) twice daily

Trizivir (AZT+3HT+Abacavir) twice daily

DRUG

Viread (300 mg Tenofovir disoproxil fumarate) once daily

Viread (300 mg Tenofovir disoproxil fumarate) once daily

Sponsors & Collaborators

  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

    collaborator OTHER

  • Germans Trias i Pujol Hospital

    lead OTHER

Principal Investigators

  • Bonaventura Clotet, MD,PhD · LLuita contra la Sida Foundation-HIV Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00356616 on ClinicalTrials.gov